In a phase II clinical trial, Dekavil (30–600 mg/kg) is administered once a week for eight consecutive weeks by subcutaneous injection in combination with MTX to RA patients who have previously failed at least one TNF inhibitor. Here, TNF is linked to rheumatoid arthritis.